What factors are contributing to the increased dropout rate in Science 37's decentralized clinical studies this month?

Introduction

The increased dropout rate in Science 37's decentralized clinical studies this month is a critical issue that demands immediate attention. As we analyze this product challenge, we'll employ a systematic framework to identify, validate, and address the root cause while considering both short-term and long-term implications for the company's clinical trial platform.

Our approach will involve a thorough examination of internal and external factors, data analysis, and hypothesis generation. We'll prioritize understanding the user journey, breaking down the metric, and formulating data-driven hypotheses. Throughout this process, we'll maintain a focus on actionable insights and solutions that can be implemented to reverse the trend and strengthen the platform's performance.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might be a seasonal effect. Has this increase in dropout rate been observed in previous years during the same month?

Why it matters: Identifying seasonal patterns helps distinguish between cyclical trends and unique issues. Expected answer: No seasonal pattern has been observed in previous years. Impact on approach: If confirmed, we'll focus on recent changes or unique circumstances this year.

• Considering the decentralized nature of the studies, I'm wondering about the geographic distribution. Has the increased dropout rate been consistent across all regions, or are there specific areas showing higher rates?

Why it matters: Geographic variations could point to region-specific issues or implementation differences. Expected answer: The increase is more pronounced in certain regions. Impact on approach: We'll investigate region-specific factors and potential localization issues.

• Thinking about the study lifecycle, I'm curious about the timing of dropouts. Are we seeing more dropouts at a particular stage of the clinical trials?

Why it matters: Identifying problematic stages helps narrow down potential causes and target interventions. Expected answer: Dropouts have increased primarily in the early stages of trials. Impact on approach: We'll focus on onboarding processes and initial engagement strategies.

• Considering recent platform changes, have there been any significant updates to the user interface or study protocols in the past month?

Why it matters: Recent changes could directly impact user experience and study participation. Expected answer: A new version of the mobile app was released two weeks ago. Impact on approach: We'll investigate the impact of the app update on user engagement and dropout rates.